samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

SHL attends the 2020 PDA in virtual fashion

SHL Group


SHL will join the 2020 Parenteral Drug Association’s annual Universe of Pre-Filled Syringes and Injection Devices virtual event with the launch of our virtual experience platform. Visitors can attend the event through the PDA’s online platform that comprises live chat sessions, conference presentations, and company pages.

In line with PDA’s digitalized strategy and in response to many inquiries from our partners and customers who have not been able to visit the SHL site due to this year’s special circumstances, SHL will also launch a webpage titled The SHL Experience to showcase the processes behind the making of our devices. The SHL Experience is rich with informative content and interactive elements, boasting our capabilities in fine machinery and expertise, while detailing our end-to-end processes, from design and development to mass production and quality control. Also, the webpage features a sophisticated design as well as a simple and intuitive interface that allows users to navigate its contents easily.

Global marketing director Magnus Fastmarken said, “The current state of the global pandemic has determined the course of digital marketing, driving companies to find new tools for effective communication with customers or business partners. For SHL, staying at the forefront of industry trends not only means providing our customers with the best products, but also finding the best way to communicate with them. SHL is poised for this new normal era.”

In addition to the premier of our virtual experience webpage, SHL experts will also give a total of four presentations while our partners at Innovation Zed will present a poster presentation at the online conference. Interested participants will have the opportunity to join our speakers at the live Q&A during the given time (EDT) for each session as follows:

 

 

Topic

Speaker

Time

Customizing Platform Devices: A Review of Molly’s Flexible Design and Development Model

Josh Gonzalez, Chief Commercial Officer, 

SHL Medical

Oct 6

11:00 am – 11:15 am Tech Talk

Characterization of a Novel Mini Bag Primary Packaging Technology

Hans Peter Manser, Senior Director of Business Development, SHL Medical 

 

Christoph Egloff, Senior Manager of Innovation and Development, SHL Medical 

Oct 7

Session A3

11:35 am – 11:55 am 

 

From Self-Administration to Self-Management:

A Digital Health Reformulation for the Drug Delivery Industry

Ramin Rafiei Ph.D., Director of Digital Healthcare, SHL Medical

Rasmus Renstad Ph.D., Director of Innovation, SHL Medical

 

Oct 7

Session C3

11:35 am – 11:55 am

 

Case Study: Key Transformation Considerations for the Design, Development, and Manufacturing of Connected Devices

Dewi Kodrat, Manager of Engineering Solutions, SHL Medical 

 

Oct 8

Session P4

10:00 am – 10:20 am 

 

Poster Presentation-Insulcheck Connect

Dean Minnock, CEO, Innovation Zed

 

Oct 5-8

12:15 pm – 2:30 pm

 Visitors are also encouraged to check into the chatroom to speak with SHL experts about our products or company information. Our experts will be standing by to answer visitors’ questions. To access The SHL experience, click here.

phone +886 3 217 0303
email info@shl-group.com
web www.shl.group
email No.136 Kuo Sheng 2nd Street, Taoyuan, Taiwan, 330
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Immunic, Inc. Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.
More info >>


White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement